Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 210852

Expand all

CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)
500MG/ML (500MG/ML)
Marketing Status: Prescription

Active Ingredient: CYCLOPHOSPHAMIDE
Proprietary Name: CYCLOPHOSPHAMIDE
Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS
Strength: 500MG/ML (500MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N210852
Product Number: 001
Approval Date: Jun 7, 2023
Applicant Holder Full Name: AVYXA HOLDINGS LLC
Marketing Status:  Prescription
Patent and Exclusivity Information

CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)
1GM/2ML (500MG/ML)
Marketing Status: Prescription

Active Ingredient: CYCLOPHOSPHAMIDE
Proprietary Name: CYCLOPHOSPHAMIDE
Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS
Strength: 1GM/2ML (500MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N210852
Product Number: 002
Approval Date: Jun 7, 2023
Applicant Holder Full Name: AVYXA HOLDINGS LLC
Marketing Status:  Prescription
Patent and Exclusivity Information

CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)
2GM/4ML (500MG/ML)
Marketing Status: Prescription

Active Ingredient: CYCLOPHOSPHAMIDE
Proprietary Name: CYCLOPHOSPHAMIDE
Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS
Strength: 2GM/4ML (500MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N210852
Product Number: 003
Approval Date: Jun 7, 2023
Applicant Holder Full Name: AVYXA HOLDINGS LLC
Marketing Status:  Prescription
Patent and Exclusivity Information